Targeting the MAPK pathway is especially interesting in lung adenocarcinoma, because these tumors have a more active MAPK pathway and more frequently harbor KRAS mutations compared with squamous cell carcinoma tumors 38, 39. Here, KRAS is linked to lung adenocarcinoma.